Pembrolizumab as Neoadjuvant Treatment in HCC

Summary

The aim of this study is to elucidate the utility of the immune checkpoint inhibitor pembrolizumab in preventing the recurrence of HCC when administered before and after curative surgery or ablation.

Timeline

Start

2017-11-10

Primary completion

2019-10-31

Completion

2020-10-31

Drugs

Indications